Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VNDA?
Source: Newsfilter
- Legislative Impact: The FDA's FY 2027 budget proposal seeks to eliminate the 180-day statutory requirement for reviewing new drug applications, which could extend review times to 10-12 months, increasing patient wait times for essential medications.
- Decreased Transparency: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially diminishing patient transparency and trust in the approval process while entrenching bureaucratic inertia over innovation.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, and this proposal aims to legalize such delays, posing greater financial risks and uncertainties for small innovators.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject it, emphasizing that it contradicts the goal of improving efficiency and could hinder patient access to necessary drugs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.290
Low
7.50
Averages
13.63
High
22.00
Current: 7.290
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VANDA PHARMACEUTICALS INC - PLAN AIMS TO REMOVE FDA'S 180-DAY NDA REVIEW OBLIGATION
- Proposal Overview: Vanda Pharmaceuticals has proposed to eliminate the FDA's 180-day new drug application (NDA) review requirement.
- Impact on Drug Approval: This change could streamline the drug approval process, potentially allowing for faster access to new medications.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's proposal in the FY 2027 budget seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review times to 10 to 12 months, which could lead to longer waits for patients needing medications.
- Review Process Changes: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially reducing transparency and increasing financial risks and uncertainties for small innovative companies like Vanda.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, yet the proposal aims to legalize these delays, indicating a disregard for the law.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject legislation that could harm patient interests and stifle innovation.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's FY 2027 budget proposal seeks to eliminate the 180-day statutory requirement for reviewing new drug applications, which could extend review times to 10-12 months, increasing patient wait times for essential medications.
- Decreased Transparency: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially diminishing patient transparency and trust in the approval process while entrenching bureaucratic inertia over innovation.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, and this proposal aims to legalize such delays, posing greater financial risks and uncertainties for small innovators.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject it, emphasizing that it contradicts the goal of improving efficiency and could hinder patient access to necessary drugs.
See More
Vanda Pharmaceuticals Initiates Thetis Trial for NEREUS in GLP-1 Therapy
- Trial Initiation: Vanda Pharmaceuticals has announced the initiation of the Thetis clinical trial to evaluate NEREUS™ (tradipitant) for preventing vomiting in patients undergoing GLP-1 receptor agonist therapy, addressing a significant barrier to treatment adherence due to nausea and vomiting.
- Efficacy Validation: In a prior Phase 2 study, only 29.3% of participants treated with tradipitant experienced vomiting compared to 58.6% in the placebo group (p=0.0016), highlighting its potential to mitigate GLP-1 related side effects and improve patient compliance.
- Multicenter Design: The Thetis study is designed as a multicenter, randomized, double-blind, placebo-controlled trial, primarily assessing the proportion of patients free from vomiting episodes during high-dose GLP-1 treatment, which is expected to provide critical data for future drug applications.
- Market Potential: With the increasing use of GLP-1 receptor agonists in diabetes and obesity treatment, the successful development of NEREUS™ could enhance patient quality of life and further strengthen Vanda's competitive position in the biopharmaceutical market.
See More
Vanda Pharmaceuticals Initiates Thetis Trial for NEREUS to Prevent Vomiting
- Trial Initiation: Vanda Pharmaceuticals has announced the initiation of the Thetis clinical trial to evaluate NEREUS™ (tradipitant) for preventing vomiting in patients receiving GLP-1 receptor agonist therapies, addressing the significant challenge of treatment discontinuation due to nausea and vomiting.
- Drug Background: Recently approved for preventing motion-induced vomiting, NEREUS™ has demonstrated potent antiemetic effects in prior studies, with the potential to improve patient tolerability to GLP-1 therapies, thereby enhancing treatment adherence.
- Trial Design: The Thetis study is a multicenter, randomized, double-blind, placebo-controlled trial primarily assessing the proportion of patients free from vomiting episodes during high-dose GLP-1 treatment, with topline results expected by Q4 2026.
- Previous Study Results: In a prior Phase 2 study, only 29.3% of patients treated with tradipitant experienced vomiting compared to 58.6% in the placebo group, indicating a 50% relative reduction and highlighting NEREUS™'s significant potential to enhance patient experience.
See More
EMA's CHMP Reaffirms Decision to Deny Change in Marketing Authorization for Hetlioz (Tasimelteon)
EMA's Recommendation: The European Medicines Agency (EMA) has confirmed its recommendation to reuse a specific change in the marketing authorization process.
Marketing Authorization: This recommendation pertains to the marketing authorization for a product associated with the organization Hetlioz, which is linked to the treatment of certain conditions.
See More
VANDA PHARMACEUTICALS INC - PLAN AIMS TO REMOVE FDA'S 180-DAY NDA REVIEW OBLIGATION
- Proposal Overview: Vanda Pharmaceuticals has proposed to eliminate the FDA's 180-day new drug application (NDA) review requirement.
- Impact on Drug Approval: This change could streamline the drug approval process, potentially allowing for faster access to new medications.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's proposal in the FY 2027 budget seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review times to 10 to 12 months, which could lead to longer waits for patients needing medications.
- Review Process Changes: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially reducing transparency and increasing financial risks and uncertainties for small innovative companies like Vanda.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, yet the proposal aims to legalize these delays, indicating a disregard for the law.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject legislation that could harm patient interests and stifle innovation.
See More
Vanda Pharmaceuticals Opposes FDA Proposal to Extend Drug Review Timelines
- Legislative Impact: The FDA's FY 2027 budget proposal seeks to eliminate the 180-day statutory requirement for reviewing new drug applications, which could extend review times to 10-12 months, increasing patient wait times for essential medications.
- Decreased Transparency: The proposal replaces the formal evidentiary hearing process with a weaker internal appeal, potentially diminishing patient transparency and trust in the approval process while entrenching bureaucratic inertia over innovation.
- Legal Compliance Issues: Vanda's CEO Polymeropoulos highlighted that the FDA's current practices have been ruled illegal by federal courts, and this proposal aims to legalize such delays, posing greater financial risks and uncertainties for small innovators.
- Call to Withdraw Proposal: Vanda urges FDA Commissioner Makary to withdraw the proposal and calls on Congress to reject it, emphasizing that it contradicts the goal of improving efficiency and could hinder patient access to necessary drugs.
See More
Vanda Pharmaceuticals Initiates Thetis Trial for NEREUS in GLP-1 Therapy
- Trial Initiation: Vanda Pharmaceuticals has announced the initiation of the Thetis clinical trial to evaluate NEREUS™ (tradipitant) for preventing vomiting in patients undergoing GLP-1 receptor agonist therapy, addressing a significant barrier to treatment adherence due to nausea and vomiting.
- Efficacy Validation: In a prior Phase 2 study, only 29.3% of participants treated with tradipitant experienced vomiting compared to 58.6% in the placebo group (p=0.0016), highlighting its potential to mitigate GLP-1 related side effects and improve patient compliance.
- Multicenter Design: The Thetis study is designed as a multicenter, randomized, double-blind, placebo-controlled trial, primarily assessing the proportion of patients free from vomiting episodes during high-dose GLP-1 treatment, which is expected to provide critical data for future drug applications.
- Market Potential: With the increasing use of GLP-1 receptor agonists in diabetes and obesity treatment, the successful development of NEREUS™ could enhance patient quality of life and further strengthen Vanda's competitive position in the biopharmaceutical market.
See More
Vanda Pharmaceuticals Initiates Thetis Trial for NEREUS to Prevent Vomiting
- Trial Initiation: Vanda Pharmaceuticals has announced the initiation of the Thetis clinical trial to evaluate NEREUS™ (tradipitant) for preventing vomiting in patients receiving GLP-1 receptor agonist therapies, addressing the significant challenge of treatment discontinuation due to nausea and vomiting.
- Drug Background: Recently approved for preventing motion-induced vomiting, NEREUS™ has demonstrated potent antiemetic effects in prior studies, with the potential to improve patient tolerability to GLP-1 therapies, thereby enhancing treatment adherence.
- Trial Design: The Thetis study is a multicenter, randomized, double-blind, placebo-controlled trial primarily assessing the proportion of patients free from vomiting episodes during high-dose GLP-1 treatment, with topline results expected by Q4 2026.
- Previous Study Results: In a prior Phase 2 study, only 29.3% of patients treated with tradipitant experienced vomiting compared to 58.6% in the placebo group, indicating a 50% relative reduction and highlighting NEREUS™'s significant potential to enhance patient experience.
See More
EMA's CHMP Reaffirms Decision to Deny Change in Marketing Authorization for Hetlioz (Tasimelteon)
EMA's Recommendation: The European Medicines Agency (EMA) has confirmed its recommendation to reuse a specific change in the marketing authorization process.
Marketing Authorization: This recommendation pertains to the marketing authorization for a product associated with the organization Hetlioz, which is linked to the treatment of certain conditions.
See More
